Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 3/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.48 |
| ▸ | IGF1R | P08069 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | DRD3 | P35462 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29342004 | 0.82 | MEN1 (0.64) | TSHRHTTALDH1A1MEN1KMT2A | |
| SCHEMBL18181904 | 0.81 | TSHR (0.63) | TSHRHTTALDH1A1MEN1KMT2A | |
| SCHEMBL25815331 | 0.81 | MAPT (0.48) | TSHRHTTALDH1A1KMT2ATP53 | |
| SCHEMBL19009086 | 0.78 | MEN1 (0.53) | TSHRHTTALDH1A1MEN1KMT2A | |
| SCHEMBL18177816 | 0.77 | ALDH1A1 (0.58) | TSHRHTTALDH1A1MEN1KMT2A | |
| SCHEMBL8370595 | 0.77 | MEN1 (0.62) | TSHRHTTALDH1A1MEN1KMT2A | |
| SCHEMBL3551183 | 0.76 | ALDH1A1 (0.61) | TSHRHTTALDH1A1MEN1KMT2A | |
| SCHEMBL13292998 | 0.75 | MEN1 (0.57) | TSHRHTTALDH1A1MEN1KMT2A | |
| SCHEMBL2650203 | 0.75 | MEN1 (0.71) | TSHRHTTALDH1A1MEN1KMT2A | |
| SCHEMBL7597607 | 0.75 | MEN1 (0.67) | TSHRHTTALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200071735-A1 | Compounds for Increasing Lipid Synthesis and Storage | WASE, NISHIKANT | 2020-03-05 | — | — | US | disclosed |
| US-10351883-B2 | Compounds for increasing lipid synthesis and storage | NUTECH VENTURES (US) | 2019-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10351883-B2 | Compounds for increasing lipid synthesis and storage | FASN, LIPC, SREBF2 | TSHR 4486/4885HTT 3738/4885ALDH1A1 1121/4885 |
| US-20200071735-A1 | Compounds for Increasing Lipid Synthesis and Storage | FASN, LIPC, SREBF2 | TSHR 4486/4885HTT 3738/4885ALDH1A1 1121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.